Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
- Kyoto Startup to Begin Clinical Trial of iPSC-Derived Platelet Agent This Year, Eyes 10 Billion Yen Biz
May 10, 2021
- Kyowa Kirin’s Q1 Sales Rise on Strong Performance Overseas
May 10, 2021
- Positive Ruling for Shionogi Now Final and Binding: Osaka Tax Suit
May 10, 2021
- Astellas’ Xtandi Earns European Approval for HSPC
May 10, 2021
- Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players
April 30, 2021
- Shionogi, InveniAI Ink Drug Discovery Collaboration
April 30, 2021
- 300 Million Yen Fine Sought for Toho Too, Court Decision Due June 2: Bid-Rigging Trial
April 30, 2021
- Takeda’s Mobocertinib Gets FDA’s Priority Review for EGFR Exon 20-Mutant NSCLC
April 30, 2021
- Pfizer Japan Posts 251 Billion Yen Sales in FY2020 after Upjohn Spinoff
April 30, 2021
- Amgen Files KRAS Inhibitor Sotorasib in Japan for NSCLC
April 30, 2021
- Court’s Settlement Offer on Opdivo Royalty Dispute Fails
April 28, 2021
- Prosecutors Seek 300 Million Yen Fine for Suzuken, Jail Terms for Employees: Bid-Rigging Trial
April 28, 2021
- Takeda, Eisai, Chemiphar Ran Early Retirement Programs over Past Year: Survey
April 28, 2021
- Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
- Daiichi Sankyo Sales Slip in FY2020 as Price Cuts, Deal Termination Weigh
April 28, 2021
- Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
April 28, 2021
- Daiichi Sankyo Gets Brazil, South Korea Rights to Esperion’s Hypercholesterolemia Drug
April 28, 2021
- AbbVie Files Maviret for Use in Children Age 3 Plus
April 28, 2021
- Nihon Generic Recalling Metformin Products over Carcinogen Risks
April 27, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…